HK1207666A1 - Rnai pharmaceutical composition capable of suppressing expression of kras gene - Google Patents
Rnai pharmaceutical composition capable of suppressing expression of kras gene Download PDFInfo
- Publication number
- HK1207666A1 HK1207666A1 HK15108285.0A HK15108285A HK1207666A1 HK 1207666 A1 HK1207666 A1 HK 1207666A1 HK 15108285 A HK15108285 A HK 15108285A HK 1207666 A1 HK1207666 A1 HK 1207666A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- enyl
- lipid
- compound
- nucleic acid
- carbon number
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261671963P | 2012-07-16 | 2012-07-16 | |
| US61/671,963 | 2012-07-16 | ||
| PCT/JP2013/069322 WO2014013995A1 (ja) | 2012-07-16 | 2013-07-16 | KRAS遺伝子発現抑制RNAi医薬組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1207666A1 true HK1207666A1 (en) | 2016-02-05 |
Family
ID=49948821
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15108285.0A HK1207666A1 (en) | 2012-07-16 | 2013-07-16 | Rnai pharmaceutical composition capable of suppressing expression of kras gene |
| HK15107660.7A HK1207113A1 (en) | 2012-07-16 | 2013-07-16 | Rnai pharmaceutical composition capable of suppressing expression of kras gene |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15107660.7A HK1207113A1 (en) | 2012-07-16 | 2013-07-16 | Rnai pharmaceutical composition capable of suppressing expression of kras gene |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9913907B2 (ja) |
| EP (1) | EP2873732A4 (ja) |
| JP (1) | JP6272226B2 (ja) |
| CN (1) | CN104471062A (ja) |
| AU (1) | AU2013291125A1 (ja) |
| CA (1) | CA2878314A1 (ja) |
| HK (2) | HK1207666A1 (ja) |
| SG (1) | SG11201502954TA (ja) |
| TW (1) | TW201408324A (ja) |
| WO (1) | WO2014013995A1 (ja) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104651362A (zh) * | 2009-04-03 | 2015-05-27 | 戴瑟纳制药公司 | 利用不对称双链rna特异性抑制kras的方法和组合物 |
| EP3153172A4 (en) * | 2014-06-04 | 2018-01-17 | Kyowa Hakko Kirin Co., Ltd. | Ckap5-gene-silencing rnai pharmaceutical composition |
| AU2015285279A1 (en) | 2014-06-30 | 2017-02-16 | Kyowa Hakko Kirin Co., Ltd. | Cationic lipid |
| EP3548005A4 (en) | 2016-11-29 | 2020-06-17 | Puretech Health LLC | Exosomes for delivery of therapeutic agents |
| EA201991804A1 (ru) | 2017-02-01 | 2020-02-07 | МОДЕРНАТиЭкс, ИНК. | ИММУНОМОДУЛИРУЮЩИЕ ТЕРАПЕВТИЧЕСКИЕ КОМПОЗИЦИИ мРНК, КОДИРУЮЩЕЙ ПЕПТИДЫ С АКТИВИРУЮЩЕЙ ОНКОГЕННОЙ МУТАЦИЕЙ |
| EP3617314B1 (en) * | 2017-04-28 | 2023-02-15 | Kyowa Kirin Co., Ltd. | Oligonucleotide derivative or salt thereof |
| AU2019226586B2 (en) * | 2018-03-02 | 2024-08-29 | Elicio Therapeutics, Inc. | Compounds including a mutant KRAS sequence and a lipid and uses thereof |
| AU2020259449A1 (en) | 2019-04-17 | 2021-12-09 | Aadigen, Llc | Peptides and nanoparticles for intracellular delivery of molecules |
| CN111534520A (zh) * | 2020-05-27 | 2020-08-14 | 深圳市疾病预防控制中心(深圳市卫生检验中心、深圳市预防医学研究所) | 特异抑制K-ras基因表达的慢病毒和重组载体构建及其应用 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1270198C (en) | 1984-08-08 | 1990-06-12 | Marcel B Bally | ENCAPSULATION OF ANTINEOPLASTIC AGENTS IN LIPOSONES |
| ZA8681B (en) | 1985-01-07 | 1987-08-26 | Syntex Inc | 1,2-dialkoxy-omega-trialkylammonium cationic surfactants |
| US5049386A (en) | 1985-01-07 | 1991-09-17 | Syntex (U.S.A.) Inc. | N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| IL91664A (en) | 1988-09-28 | 1993-05-13 | Yissum Res Dev Co | Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release |
| JP2923296B2 (ja) | 1988-11-14 | 1999-07-26 | 株式会社ビタミン研究所 | 細胞への遺伝子導入法 |
| JPH0696670B2 (ja) | 1988-11-16 | 1994-11-30 | 日本ポリウレタン工業株式会社 | 反応性安定化ポリオール組成物 |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| US6469158B1 (en) | 1992-05-14 | 2002-10-22 | Ribozyme Pharmaceuticals, Incorporated | Synthesis, deprotection, analysis and purification of RNA and ribozymes |
| US5977343A (en) | 1992-05-14 | 1999-11-02 | Ribozyme Pharmaceuticals, Inc. | Synthesis, deprotection, analysis and purification of RNA and ribozymes |
| US5804683A (en) | 1992-05-14 | 1998-09-08 | Ribozyme Pharmaceuticals, Inc. | Deprotection of RNA with alkylamine |
| ATE227342T1 (de) | 1993-09-02 | 2002-11-15 | Ribozyme Pharm Inc | Enzymatische nukleiksaüre die nicht-nukleotide enthaltet |
| US5889136A (en) | 1995-06-09 | 1999-03-30 | The Regents Of The University Of Colorado | Orthoester protecting groups in RNA synthesis |
| WO1997019675A2 (en) | 1995-11-30 | 1997-06-05 | Vical Incorporated | Complex cationic lipids |
| US5998203A (en) | 1996-04-16 | 1999-12-07 | Ribozyme Pharmaceuticals, Inc. | Enzymatic nucleic acids containing 5'-and/or 3'-cap structures |
| EP1027033B1 (en) | 1997-05-14 | 2009-07-22 | The University Of British Columbia | High efficiency encapsulation of nucleic acids in lipid vesicles |
| TWI225412B (en) | 1997-06-23 | 2004-12-21 | Sequus Pharm Inc | Liposome-entrapped polynucleotide composition and method |
| US6111086A (en) | 1998-02-27 | 2000-08-29 | Scaringe; Stephen A. | Orthoester protecting groups |
| US6656498B1 (en) * | 1998-11-25 | 2003-12-02 | Vanderbilt University | Cationic liposomes for gene transfer |
| EP1309726B2 (en) | 2000-03-30 | 2018-10-03 | Whitehead Institute For Biomedical Research | Rna sequence-specific mediators of rna interference |
| CN1284523C (zh) | 2000-10-04 | 2006-11-15 | 协和发酵工业株式会社 | 由脂质膜被覆微粒的方法 |
| US20020132788A1 (en) | 2000-11-06 | 2002-09-19 | David Lewis | Inhibition of gene expression by delivery of small interfering RNA to post-embryonic animal cells in vivo |
| DK1409506T3 (da) | 2001-07-23 | 2012-08-06 | Univ Leland Stanford Junior | Fremgangsmåder og sammensætninger til RNAi-formidlet inhibering af genekspression i pattedyr |
| WO2005121348A1 (en) | 2004-06-07 | 2005-12-22 | Protiva Biotherapeutics, Inc. | Lipid encapsulated interfering rna |
| KR20070104575A (ko) | 2005-01-28 | 2007-10-26 | 교와 핫꼬 고교 가부시끼가이샤 | 표적 유전자의 발현을 억제하는 조성물 |
| GB0505969D0 (en) | 2005-03-23 | 2005-04-27 | Novartis Ag | Organic compounds |
| WO2008109516A2 (en) * | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting ras gene expression and uses thereof |
| US20110117125A1 (en) * | 2008-01-02 | 2011-05-19 | Tekmira Pharmaceuticals Corporation | Compositions and methods for the delivery of nucleic acids |
| AU2009336191B2 (en) * | 2008-12-18 | 2017-08-24 | Novo Nordisk A/S | Extended dicer substrate agents and methods for the specific inhibition of gene expression |
| CN104651362A (zh) | 2009-04-03 | 2015-05-27 | 戴瑟纳制药公司 | 利用不对称双链rna特异性抑制kras的方法和组合物 |
| EP2567951B1 (en) | 2010-04-28 | 2018-09-19 | Kyowa Hakko Kirin Co., Ltd. | Cationic lipid |
| WO2013089151A1 (ja) * | 2011-12-12 | 2013-06-20 | 協和発酵キリン株式会社 | カチオン性脂質を含有するドラッグデリバリーシステムのための脂質ナノ粒子 |
| KR20140111272A (ko) | 2011-12-12 | 2014-09-18 | 교와 핫꼬 기린 가부시키가이샤 | 양이온성 지질의 조합을 함유하는 지질 나노 입자 |
-
2013
- 2013-07-16 AU AU2013291125A patent/AU2013291125A1/en not_active Abandoned
- 2013-07-16 CA CA2878314A patent/CA2878314A1/en not_active Abandoned
- 2013-07-16 JP JP2014525829A patent/JP6272226B2/ja not_active Expired - Fee Related
- 2013-07-16 WO PCT/JP2013/069322 patent/WO2014013995A1/ja not_active Ceased
- 2013-07-16 HK HK15108285.0A patent/HK1207666A1/en unknown
- 2013-07-16 US US13/943,038 patent/US9913907B2/en not_active Expired - Fee Related
- 2013-07-16 TW TW102125430A patent/TW201408324A/zh unknown
- 2013-07-16 EP EP13820367.4A patent/EP2873732A4/en not_active Withdrawn
- 2013-07-16 CN CN201380037777.9A patent/CN104471062A/zh active Pending
- 2013-07-16 HK HK15107660.7A patent/HK1207113A1/xx unknown
- 2013-07-16 SG SG11201502954TA patent/SG11201502954TA/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN104471062A (zh) | 2015-03-25 |
| JP6272226B2 (ja) | 2018-01-31 |
| JPWO2014013995A1 (ja) | 2016-07-07 |
| TW201408324A (zh) | 2014-03-01 |
| EP2873732A1 (en) | 2015-05-20 |
| AU2013291125A1 (en) | 2015-01-22 |
| CA2878314A1 (en) | 2014-01-23 |
| EP2873732A4 (en) | 2016-03-23 |
| US20140044755A1 (en) | 2014-02-13 |
| SG11201502954TA (en) | 2015-05-28 |
| US9913907B2 (en) | 2018-03-13 |
| WO2014013995A1 (ja) | 2014-01-23 |
| HK1207113A1 (en) | 2016-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9839616B2 (en) | Lipid nano particles comprising cationic lipid for drug delivery system | |
| CN104159615B (zh) | 含有阳离子性脂质的组合的脂质纳米粒子 | |
| EP2871178B1 (en) | Cationic lipid | |
| US9913907B2 (en) | RNAi pharmaceutical composition for suppressing expression of KRAS gene | |
| EP3153172A1 (en) | Ckap5-gene-silencing rnai pharmaceutical composition | |
| KR20170023004A (ko) | 양이온성 지질 | |
| JP2018065789A (ja) | カチオン性脂質 | |
| JPWO2017111172A1 (ja) | カチオン性脂質としての化合物 | |
| US20140294978A1 (en) | Cationic lipid | |
| WO2018225873A1 (ja) | 核酸含有ナノ粒子 |